首页> 外文期刊>Current neuropharmacology >Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: A True Effect or a Bias? A Systematic Review & Meta-Analysis
【24h】

Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: A True Effect or a Bias? A Systematic Review & Meta-Analysis

机译:怀孕期间选择性血清素再摄取抑制剂(SSRIS)和血清素Norepinephrine再摄取抑制剂(SNRIS)以及后代的自闭症谱系障碍(ASD)和注意力缺陷多动障碍(ADHD)的风险:真正的效果或偏见? 系统评价& 荟萃分析

获取原文
           

摘要

Background and Objective An inconsistent association between exposure to SSRIs and SNRIs and the risk for ASD and ADHD in the Offspring was observed in observational studies. Some suggest that the reported association might be due to unmeasured confounding. We aimed to study this association and to look for sources of bias by performing a systematic review and meta-analysis. Methods Medline, Embase, and the Cochrane Library were searched up to June 2019 for studies reporting on ASD and ADHD in the Offspring following exposure during pregnancy. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random-effects models and odds ratios (OR), and 95% confidence intervals (CI) were calculated for each outcome using the adjusted point estimate of each study. Results Eighteen studies were included in the meta-analysis. We found an association between SSRIs/SNRIs prenatal use and the risk for ASD and ADHD (OR=1.42, 95% CI: 1.23–1.65, I ~(2)=58%; OR=1.26, 95% CI: 1.07-1.49, I ~(2)=48%, respectively). Similar findings were obtained in women who were exposed to SSRIs/SNRIs before pregnancy, representing statistically significant association with ASD (OR=1.39, 95% CI: 1.24-1.56, I ~(2)=33%) and ADHD (OR=1.63, 95% CI: 1.50-1.78, I ~(2)=0%) in the Offspring, although they were not exposed to those medications in utero. Conclusions Although we found an association between exposure to SSRIs/SNRIs during pregnancy and the risk for ASD and ADHD, an association with those disorders was also present for exposure pre-pregnancy, suggesting that the association might be due to unmeasured confounding. We are aiming to further assess the role of potential unmeasured confounding in the estimation of the association and perform a network meta-analysis.
机译:背景技术在观察研究中观察到接触SSRIS和SNRI之间的不一致关联以及后代和后代ASD和ADHD的风险。有些人建议报告的协会可能是由于未测量的混乱。我们旨在通过执行系统审查和荟萃分析来研究这一协会并寻找偏差来源。方法Medline,Embase和Cochrane图书馆截至2019年6月,研究了在怀孕期间暴露后的后代和ADHD的研究。我们跟随Prisma 2009的数据选择和提取指南。使用随机效应模型和多种置信度(或)汇集结果,并使用每项研究的调整点估计计算每个结果的95%置信区间(CI)。结果在Meta分析中包含18项研究。我们发现SSRIS / SNRIS产前使用与ASD和ADHD风险(或= 1.42,95%CI:1.23-1.65,I〜(2)= 58%;或= 1.26,95%CI:1.07-1.49 ,i〜(2)分别= 48%)。在妊娠之前暴露于SSRIS / SNRIS的女性中获得了类似的结果,其与ASD(或= 1.39,95%CI:1.24-1.56,I〜(2)= 33%)和ADHD(或= 1.63 ,95%CI:1.50-1.78,I〜(2)= 0%)在后代,虽然它们没有暴露于子宫中的那些药物。结论虽然我们在怀孕期间发现暴露于SSRIS / SNRIS之间的关联以及ASD和ADHD的风险,但与那些障碍的关联也出现了暴露前孕期,这表明该协会可能是由于未测量的混淆。我们旨在进一步评估潜在未测量混淆在估计协会中的作用,并进行网络元分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号